Clinical Trials Logo

HR-positive Breast Cancer clinical trials

View clinical trials related to HR-positive Breast Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05508906 Recruiting - Clinical trials for Metastatic Breast Cancer

Phase 1b Combo w/ Ribociclib and Alpelisib

Start date: August 31, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation).